{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:37:59Z","timestamp":1782135479625,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bictegravir (BIC) co-formulated with emtricitabine (FTC) and tenofovir alafenamide (TAF) is approved by Federal Food and Drug Administration in 2018 for both treatment-na\u00efve and experienced persons living with HIV (PLWH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A young man with recently diagnosed human immunodeficiency virus (HIV) infection presented with jaundice. Blood work was significant for mild anemia and grade 4 unconjugated hyperbilirubinemia. A comprehensive evaluation for hemolytic anemia failed to reveal any etiology. Other causes of hyperbilirubinemia were negative. Four months prior, patient was started on antiretroviral therapy with a single tablet regimen containing bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF), brand name Biktarvy\n                      <jats:sup>\u00ae<\/jats:sup>\n                      , and the medication was suspected to be the cause. The medication was held, and the hyperbilirubinemia improved.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Severe hyperbilirubinemia can be found in the patient using BIC\/FTC\/TAF. The data for this adverse reaction is scarce, and more studies are needed on this possible side effect. The mechanism of unconjugated hyperbilirubinemia by INSTI remains undefined.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12981-023-00501-7","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T12:02:40Z","timestamp":1674475360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A possible case of bictegravir-associated severe unconjugated hyperbilirubinemia"],"prefix":"10.1186","volume":"20","author":[{"given":"Kanak","family":"Parmar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poemlarp","family":"Mekraksakit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Nugent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"501_CR1","unstructured":"https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2018\/2\/us-food-and-drug-administration-approves-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-treatment-of-hiv1-infection. Accessed 7 Feb 2018."},{"key":"501_CR2","unstructured":"https:\/\/www.natap.org\/2018\/HIV\/032818_01.htm."},{"issue":"16","key":"501_CR3","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jama.2020.17025","volume":"324","author":"MS Saag","year":"2020","unstructured":"Saag MS, Gandhi RT, Hoy JF, Landovitz RJ, Thompson MA, Sax PE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society-USA panel. JAMA. 2020;324(16):1651\u201369.","journal-title":"JAMA"},{"issue":"5","key":"501_CR4","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3390\/cells10051263","volume":"10","author":"AO Otto","year":"2021","unstructured":"Otto AO, Rivera CG, Zeuli JD, Temesgen Z. Hepatotoxicity of contemporary antiretroviral drugs: a review and evaluation of published clinical data. Cells. 2021;10(5):1263. https:\/\/doi.org\/10.3390\/cells10051263.","journal-title":"Cells"},{"issue":"6","key":"501_CR5","first-page":"430","volume":"2","author":"GW Neff","year":"2006","unstructured":"Neff GW, Jayaweera D, Sherman KE. Drug-Induced liver injury in HIV patients. Gastroenterol Hepatol. 2006;2(6):430\u20137.","journal-title":"Gastroenterol Hepatol"},{"key":"501_CR6","unstructured":"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead sciences March 2021."},{"issue":"10107","key":"501_CR7","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"PE Sax","year":"2017","unstructured":"Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073\u201382.","journal-title":"Lancet"},{"issue":"2","key":"501_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"10107","key":"501_CR9","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063\u201372.","journal-title":"Lancet"},{"issue":"1","key":"501_CR10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1053\/jhep.2002.30319","volume":"35","author":"MS Sulkowski","year":"2002","unstructured":"Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35(1):182\u20139.","journal-title":"Hepatology"},{"issue":"1","key":"501_CR11","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/S2352-3018(19)30336-4","volume":"7","author":"JM Molina","year":"2020","unstructured":"Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV. 2020;7(1):e16\u201326.","journal-title":"Lancet HIV"},{"issue":"5","key":"501_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1089\/apc.2011.0092","volume":"26","author":"C McDonald","year":"2012","unstructured":"McDonald C, Uy J, Hu W, Wirtz V, Juethner S, Butcher D, et al. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir\/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDs. 2012;26(5):259\u201364.","journal-title":"AIDS Patient Care STDs"},{"issue":"7","key":"501_CR13","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1053\/j.gastro.2014.03.047","volume":"146","author":"S Erlinger","year":"2014","unstructured":"Erlinger S, Arias IM, Dhumeaux D. Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences. Gastroenterology. 2014;146(7):1625\u201338.","journal-title":"Gastroenterology"},{"issue":"1","key":"501_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.antiviral.2009.09.001","volume":"85","author":"V Tozzi","year":"2010","unstructured":"Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res. 2010;85(1):190\u2013200.","journal-title":"Antiviral Res"},{"issue":"2","key":"501_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cbi.2004.08.008","volume":"150","author":"SD Campbell","year":"2004","unstructured":"Campbell SD, de Morais SM, Xu JJ. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact. 2004;150(2):179\u201387.","journal-title":"Chem Biol Interact"},{"issue":"4","key":"501_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","volume":"85","author":"G Rizzardini","year":"2020","unstructured":"Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, G\u00f3rgolas Hern\u00e1ndez-Mora M, et al. Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials. J Acquir Immune Defic Syndr. 2020;85(4):498\u2013506.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"501_CR17","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.3390\/toxins7051616","volume":"7","author":"R Bissinger","year":"2015","unstructured":"Bissinger R, Waibel S, Lang F. Induction of suicidal erythrocyte death by nelfinavir. Toxins. 2015;7(5):1616\u201328.","journal-title":"Toxins"},{"issue":"4","key":"501_CR18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/00002030-200003100-00024","volume":"14","author":"A Watson","year":"2000","unstructured":"Watson A. Reversible acute haemolysis associated with indinavir. AIDS. 2000;14(4):465\u20136.","journal-title":"AIDS"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-023-00501-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-023-00501-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-023-00501-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T12:04:15Z","timestamp":1674475455000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-023-00501-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["501"],"URL":"https:\/\/doi.org\/10.1186\/s12981-023-00501-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1731898\/v1","asserted-by":"object"}]},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"assertion":[{"value":"7 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent has been acquired by the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}